Treatment Center: NeuroCentrix
Location: 1 Beck Court, Noble Park, VIC
Lead Doctors: Professor David Barton and Dr Peter Farnbach

Background

Alzheimer’s disease is the most common cause of dementia. A recently approved treatment has preliminary data that has shown some improvement in the cognitive abilities of those patients.  

The NeuroADTM Therapy System is an innovative treatment for mild to moderate Alzheimer’s disease. Studies have shown that using this treatment demonstrates some improvements in patients’ cognitive performance. This therapy combines computerised cognitive training with repetitive transcranial magnetic stimulation (rTMS). rTMS is a form of brain stimulation therapy that involves using a magnet to target and stimulate certain areas of the brain.

This therapy is available for adults experiencing symptoms of early Alzheimer’s Disease or mild cognitive impairment. Those that would like to obtain the most effect of the therapy are asked to attend 30 sessions which are scheduled five days per week for six weeks. The sessions last approximately 1.5hrs.

Why Consider This Treatment?

• This treatment has minimal side effects
• Studies have shown that it is well tolerated by patients
• You can continue taking your other Alzheimer’s medications
• Preliminary data showed that this treatment may have potential benefits for patients with early Alzheimer’s disease.
• Has been approved for use in Australia by the Therapeutic Goods Administration and is CE-cleared and commercially available in Europe.

Your Rights

• If you decide to receive treatment and later feel that you would like to stop receiving treatment, you can stop at any time, however the results are not guaranteed if the treatment is prematurely stopped.
• Those patients who cannot tolerate the treatment or discontinue due to a medical reason will be refunded for the uncompleted sessions. If you decide to stop treatment due to changing your mind or stop attending with no notice, there will not be a refund.
• Your records relating to this treatment and any other information received will be kept strictly confidential, except as required by the law.
• Qualified health professionals will monitor your health as it relates to the treatment.

Who Is Eligible To Receive This Treatment?

• Patients with mild to moderate Alzheimer’s disease or Mild Cognitive Impairment due to Alzheimer’s disease
• Patients experiencing symptoms of early Alzheimer’s Disease
• Must be able to undergo an MRI scan
• Do not have a history of epilepsy or fitted cardiac demand pacemakers.
• Able to attend daily 1-hour visits (5 times a week)  at the treatment site within a period of approximately 6 weeks.